Achao­gen slow­ly soars, speed­ing top an­tibi­ot­ic to FDA/EMA af­ter PhI­II scores pos­i­tive re­sults

South San Fran­cis­co-based Achao­gen says its lead an­tibi­ot­ic pla­zomicin scored pos­i­tive Phase III ef­fi­ca­cy and safe­ty da­ta, set­ting it up for mar­ket­ing ap­pli­ca­tions on both sides of the At­lantic. And the stock price be­gan to rise im­me­di­ate­ly, steadi­ly gain­ing speed through­out the day be­fore clos­ing up a whop­ping 148%.

Achao­gen $AKAO is one of a hand­ful of biotechs in late-stage de­vel­op­ment with new an­tibi­otics in an era of ris­ing drug re­sis­tance to the main­stays in the field. Its top gram-neg­a­tive can­di­date scored on non-in­fe­ri­or­i­ty to meropen­em for the FDA re­quire­ments and looked su­pe­ri­or by EMA stan­dards on com­pli­cat­ed uri­nary tract in­fec­tions (cU­TI) and acute pyelonephri­tis (AP).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER